hVIVO’s (HVO) “Buy” Rating Reiterated at Peel Hunt

Peel Hunt restated their buy rating on shares of hVIVO (LON:HVO) in a research report report published on Monday morning,Digital Look reports. Peel Hunt currently has a GBX 14 target price on the stock.

hVIVO Price Performance

Shares of LON HVO opened at GBX 5.84 on Monday. hVIVO has a twelve month low of GBX 4.30 and a twelve month high of GBX 11. The stock’s 50 day moving average price is GBX 6.42 and its 200-day moving average price is GBX 7.15. The company has a market capitalization of £40.20 million, a PE ratio of -3.28 and a beta of 1.69. The company has a quick ratio of 1.16, a current ratio of 1.21 and a debt-to-equity ratio of 43.38.

hVIVO (LON:HVO) last released its earnings results on Tuesday, September 15th. The company reported GBX (0.82) earnings per share (EPS) for the quarter. hVIVO had a negative net margin of 31.76% and a negative return on equity of 35.13%. On average, equities analysts anticipate that hVIVO will post 1.55 EPS for the current year.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.